Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 127

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 4
Chunk 127
---
, both on our proprietarily developed projects and
improvement to our in-licensed projects.

The following table sets forth
a list of our patent rights under the exclusive licenses as of the date of this annual report related to our Lead Projects, ALS-4 and
PathsDxTest; on the other hand, our other Lead Project, SACT-1 is a proprietary technology not subject to any license agreement:

  Project               License Agreement                                                        Licensor(s)                          Licensee                            Licensed / IP Rights                                                                                                                                                                                      Patent Expiration Dates                                                                                                                                                                               
  Company                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 
  / Project                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
  name                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    
  Acticule / ALS-4      Exclusive Patent License Agreement, dated October 18, 2017 First         Versitech Limited                    Acticule Life Sciences Limited      Exclusive licensee: 4 US patents (US10471045, US11446280, US11052078, US11040949), 2 PRC patents (ZL201880048665.6, ZL201880048674.5), 2 Japanese patents (JP7232238, JP 7348893), 2 Israeli pate...      The licensed IP rights include granted patents                                                                                                                                                        
                        Amendment to Exclusive License Agreement, dated June 7, 2018                                                                                                                                                                                                                                                                                                in the US, PRC, Japan, Israel, and pending patent applications in 3 other foreign jurisdictions.                                                                                                      
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                        Second Amendment to Exclusive License Agreement dated July 10, 2019                                                                                                                                                                                                                                                                                         The U. S. patents will expire in 2038-2040. Any                                                                                                                                                       
                                                                                                                                                                                                                                                                                                                                                                                    other patents derived from the pending applications, if granted, will have a 20-year patent term from 2018.                                                                                           
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
                        Exclusive Patent License Agreement dated January 11, 2019                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Paths Dx              Exclusive Patent License Agreement, dated September 25, 2020             Accelerate Technologies Pte Ltd      Paths Diagnostics Pte. Limited      Exclusive licensee: 4 U. S. patents (US7635566, US8241850, US9920355, US10472667, US11,280,028), 1 European patent (EP3224374), 1 Great Britain patent (GB2532749) and 12 pending applications